SYRE — Spyre Therapeutics, Inc.
6 mentions in the last 24 hours · 0.03% of all mentions
Why people talked about SYRE (2026-11-04)
- Spyre Therapeutics announced Q3 2026 earnings results, reporting an EPS of -$0.94 which missed estimates.
- The company's clinical readout for the SPY072 SKYWAY PsA sub-study missed its primary endpoint, leading to no further plans in rheumatic diseases.
- Revenue was reported as $0, and the company issued a press release detailing these financial results for the quarter ended September 30, 2026.
| Bluesky | 3 | community |
| GDELT | 2 | news |
| SEC EDGAR 8-K | 1 | filings |